COMMUNIQUÉS West-GlobeNewswire

-
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
26/03/2025 -
Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe
26/03/2025 -
Financière de Tubize - Convening of the ordinary and extraordinary general meetings of shareholders of April 25, 2025
26/03/2025 -
Financière de Tubize - Convocation aux assemblées générales ordinaire et extraordinaire du 25/04/2025
26/03/2025 -
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
26/03/2025 -
Microbix Further Optimizes Capital Usage and Availability
26/03/2025 -
Hair Loss Hero: 2DDR HEALTHCARE Shares Results From Customer Driven Hair Loss Research Study
26/03/2025 -
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
26/03/2025 -
Zymeworks Announces Participation in Upcoming Investor Conferences
26/03/2025 -
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26/03/2025 -
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26/03/2025 -
FDA Issues Nyxoah an Approvable Letter for its Genio® System
26/03/2025 -
La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système Genio®
26/03/2025 -
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia
26/03/2025 -
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility
26/03/2025 -
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26/03/2025 -
Communiqué de presse : La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia
26/03/2025 -
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
26/03/2025 -
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
26/03/2025
Pages